Protocol Ledger

NCT04566445 · Phase II · TERMINATED

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Interventional Phase II clinical trial protocol NCT04566445 sponsored by Novartis in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-28 Enrollment: 255 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04566445
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)255 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04566445
Protocol FieldVerified Registry Value
NCT IdentifierNCT04566445
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment255 participants (ACTUAL)
Registered Start Date2020-09-28
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI